



Physiomics Plc  
The Magdalen Centre  
The Oxford Science Park  
Robert Robinson Avenue  
Oxford  
OX4 4GA  
UK

27<sup>th</sup> March 2019

Physiomics plc

("Physiomics") or ("the Company")

### Issue of Options

The Company considers that the award of options linked to company performance are critical to the incentivisation of its senior employees and to ensure that there is alignment between management and shareholders. To this end, the Company today confirms that it has agreed to issue share options to its directors, as detailed in this announcement. Each option forming part of this award is exercisable at a price of 3.16p, being the greater of (i) the average closing price for the three dealing days immediately preceding the date of grant; and (ii) the closing price on the dealing day immediately prior to the date of grant.

1. 400,000 share options over ordinary shares in the Company have been granted to Dr James Millen under the Enterprise Management Initiative Scheme ("EMI")
2. 267,000 share options over ordinary shares in the Company have been granted to Dr Christophe Chassagnole under the Enterprise Management Initiative Scheme ("EMI")

The options vest based on a combination of performance and time-based criteria and can be exercised within 10 years of the date of grant.

Following this issue, Jim Millen will hold options over 2,373,923 ordinary shares of the Company and Christophe Chassagnole will hold options over 1,879,533 ordinary shares in the Company in accordance with the table below:

Option holder	# Options	Exercise price(p)	Expiry date
J Millen	1,453,923	2.500	27-Feb-27
	520,000	5.350	26-Mar-28
	400,000	3.160	26-Mar-29
C Chassagnole	118,565	40.000	29-Feb-20
	32,331	34.000	08-Nov-21
	129,381	13.200	11-Feb-23
	322,615	6.167	23-Mar-25

659,641	2.500	27-Feb-27
350,000	5.350	26-Mar-28
267,000	3.160	26-Mar-29

In addition, Jim Millen owns 444,641 ordinary shares (equivalent to 0.62% of the currently issued share capital) and Christophe Chassagnole owns 417,008 ordinary shares (equivalent to 0.58% of the currently issued share capital).

The total number of shares in issue remains 71,910,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.

Enquiries:

**Physiomics plc**

Dr Jim Millen, CEO  
+44 (0)1865 784 980

**WH Ireland Limited (nomad)**

Katy Mitchell  
+44 (0) 161 832 2174

**Hybridan LLP (broker)**

Claire Louise Noyce  
+44 (0) 203 764 2341

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING  
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	Dr James Millen	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	CEO	
b)	Initial notification/ Amendment	Initial	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Physiomics PLC	
b)	LEI	213800A71DSZ6ABMTQ91	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument  Identification code	Options over Ordinary Shares  GB00BDR6W943	
b)	Nature of the transaction	Issue of options	
c)	Price(s) and volume(s)	<b>Price(s)</b>	<b>Volume(s)</b>
		3.16 pence	400,000
d)	Aggregated information - Aggregated volume - Price	<ul style="list-style-type: none"> <li>• 400,000</li> <li>• 3.16 pence</li> </ul>	
e)	Date of the transaction	27 March 2019	
f)	Place of the transaction	London, AIM	

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING  
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	Dr Christophe Chassagnole	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	COO	
b)	Initial notification/ Amendment	Initial	

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Physiomics PLC	
b)	LEI	213800A71DSZ6ABMTQ91	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument  Identification code	Options over Ordinary Shares  GB00BDR6W943	
b)	Nature of the transaction	Issue of options	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		3.16 pence	267,000
d)	Aggregated information - Aggregated volume - Price	<ul style="list-style-type: none"> <li>• 267,000</li> <li>• 3.16 pence</li> </ul>	
e)	Date of the transaction	27 March 2019	
f)	Place of the transaction	London, AIM	

### About Physiomics plc

Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 70 projects, involving over 30 targets and 60 drugs.

Based in Oxford, UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics' senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals.

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.